JP2015515490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515490A5 JP2015515490A5 JP2015507659A JP2015507659A JP2015515490A5 JP 2015515490 A5 JP2015515490 A5 JP 2015515490A5 JP 2015507659 A JP2015507659 A JP 2015507659A JP 2015507659 A JP2015507659 A JP 2015507659A JP 2015515490 A5 JP2015515490 A5 JP 2015515490A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 49
- 150000001413 amino acids Chemical class 0.000 claims 41
- 239000012634 fragment Substances 0.000 claims 23
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 101000650590 Homo sapiens Roundabout homolog 4 Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100027701 Roundabout homolog 4 Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000010595 endothelial cell migration Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 101150050515 Robo4 gene Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 102000049707 human ROBO4 Human genes 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015507659A JP5897205B2 (ja) | 2012-04-27 | 2013-04-26 | 抗ｒｏｂｏ４抗体 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012103929A JP2013230115A (ja) | 2012-04-27 | 2012-04-27 | 抗ｒｏｂｏ４抗体 |
| JP2012103929 | 2012-04-27 | ||
| JP2013011042A JP2014141434A (ja) | 2013-01-24 | 2013-01-24 | 抗ｒｏｂｏ４抗体 |
| JP2013011042 | 2013-01-24 | ||
| PCT/IB2013/053312 WO2013160879A1 (en) | 2012-04-27 | 2013-04-26 | Anti-robo4-antibody |
| JP2015507659A JP5897205B2 (ja) | 2012-04-27 | 2013-04-26 | 抗ｒｏｂｏ４抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016038918A Division JP6267733B2 (ja) | 2012-04-27 | 2016-03-01 | 抗ｒｏｂｏ４抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515490A JP2015515490A (ja) | 2015-05-28 |
| JP2015515490A5 true JP2015515490A5 (cg-RX-API-DMAC10.html) | 2015-09-24 |
| JP5897205B2 JP5897205B2 (ja) | 2016-03-30 |
Family
ID=48670623
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507659A Expired - Fee Related JP5897205B2 (ja) | 2012-04-27 | 2013-04-26 | 抗ｒｏｂｏ４抗体 |
| JP2016038918A Expired - Fee Related JP6267733B2 (ja) | 2012-04-27 | 2016-03-01 | 抗ｒｏｂｏ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016038918A Expired - Fee Related JP6267733B2 (ja) | 2012-04-27 | 2016-03-01 | 抗ｒｏｂｏ４抗体 |
Country Status (22)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN07799A (cg-RX-API-DMAC10.html) * | 2012-04-27 | 2015-05-15 | Daiichi Sankyo Co Ltd | |
| CN110922481A (zh) | 2015-09-24 | 2020-03-27 | 第一三共株式会社 | 抗garp抗体 |
| WO2018070390A1 (ja) | 2016-10-12 | 2018-04-19 | 第一三共株式会社 | 抗ｒｏｂｏ４抗体と他剤を含む組成物 |
| KR20210070643A (ko) | 2019-12-05 | 2021-06-15 | 김명배 | 자체 발전 웨어러블 다리 |
| US20250066471A1 (en) | 2022-02-16 | 2025-02-27 | Institut National de la Santé et de la Recherche Médicale | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
| WO2025045139A1 (zh) * | 2023-08-31 | 2025-03-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别robo2的抗体及其应用 |
| CN117384290B (zh) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| ATE360068T1 (de) * | 2000-11-06 | 2007-05-15 | Cancer Rec Tech Ltd | Bildgebende verfahren, diagnose und behandlung von krankheiten |
| JP4583638B2 (ja) | 2001-03-15 | 2010-11-17 | 独立行政法人科学技術振興機構 | アセチルリジン認識モノクローナル抗体及びその製造方法 |
| WO2004003163A2 (en) | 2002-06-27 | 2004-01-08 | University Of Utah Research Foundation | Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| US20060099143A1 (en) | 2002-11-20 | 2006-05-11 | Roy Bicknell | Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis |
| EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| JP2010512327A (ja) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 病的血管形成および脈管透過性の処置用の組成物および方法 |
| US7834154B2 (en) * | 2007-02-09 | 2010-11-16 | Genentech, Inc. | Anti-ROBO4 antibodies and uses therefor |
| TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| IN2014DN07799A (cg-RX-API-DMAC10.html) * | 2012-04-27 | 2015-05-15 | Daiichi Sankyo Co Ltd |
-
2013
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/ko not_active Expired - Fee Related
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/pt not_active Application Discontinuation
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/ko not_active Ceased
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/da active
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en not_active Not-in-force
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en not_active Ceased
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 TW TW102115219A patent/TWI606065B/zh not_active IP Right Cessation
- 2013-04-26 PL PL13730645T patent/PL2841457T3/pl unknown
- 2013-04-26 ES ES13730645T patent/ES2733434T3/es active Active
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 MX MX2014012351A patent/MX356749B/es active IP Right Grant
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/ja not_active Expired - Fee Related
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/zh not_active Expired - Fee Related
- 2013-04-26 US US14/397,210 patent/US9683040B2/en not_active Expired - Fee Related
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/ru not_active IP Right Cessation
-
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382B1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/es unknown
-
2015
- 2015-12-11 US US14/966,292 patent/US9562096B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/ja not_active Expired - Fee Related